Pharma's AI Adoption Hits Governance and Execution Roadblocks…

Event summary

Trinity's 2025 CMIT survey found 100% of pharma organizations have adopted generative AI, but only 3/5 confidence in innovation readiness.
66% lack dedicated Chief Digital or AI Officers, limiting execution accountability.
Less than 25% of digital budgets allocated to innovation, constraining scaling efforts.
AI governance remains fragmented, creating regulatory risk gaps.

The big picture

While AI has become table stakes in pharma, the industry faces a critical inflection point where governance, data foundations, and operational discipline will determine competitive advantage. Companies that successfully align these elements stand to gain in commercialization, patient engagement, and operational efficiency, while laggards risk compliance exposure and higher costs. This marks a shift from AI experimentation to operationalization across the sector.

What we're watching

Governance Dynamics: How pharma companies will formalize AI governance frameworks before regulatory scrutiny intensifies.
Execution Risk: Whether organizations without dedicated digital/AI leadership can achieve enterprise-scale AI impact.
Value Realization: The pace at which pharma companies will demonstrate measurable business value from AI investments.